Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update

Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Transplant
Asıl Yazarlar: Holdaas, Hallvard, De Simone, Paolo, Zuckermann, Andreas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Hindawi Publishing Corporation 2016
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/
https://ncbi.nlm.nih.gov/pubmed/27807479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller